Expression of c-kit protein in cancer vs. normal breast tissue

被引:3
作者
Talaiezadeh, Abdolhassan [1 ]
Jazayeri, Seyed Nematollah [2 ]
Nateghi, Jamal
机构
[1] Ahvaz Jundishapur Univ Med Sci, Dept Surg, Imam Khomeini Hosp, Ahvaz, Iran
[2] Ahvaz Jundishapur Univ Med Sci, Ahvaz, Iran
来源
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2012年 / 16卷 / 04期
关键词
C-kit protein; breast cancer; imatinib; ductal carcinoma; STEM-CELL FACTOR; PROTOONCOGENE PRODUCT; RECEPTOR; LESIONS; BENIGN; SCF;
D O I
10.5114/wo.2012.30058
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim of the study: There are at least four main signal transduction pathways within human cells which are activated by interaction of an extracellular ligand with its corresponding receptors. One of them is activation of protein kinase. Actually, any of these proteins at any level of the signaling cascade in a human cell can undergo mutation and cause irregular cellular proliferation and finally result in cancer. C-kit is alternatively called stem cell factor receptor (SCFR) or CD117. It appears that lack of c-kit expression accompanies progression of some tumors, e.g. lung, breast, GIST The aim of this study was to evaluate C-kit protein expression level within cancer cases. Material and methods: Sixty specimens of breast cancer and 60 non-cancerous breast tissue specimens were evaluated by IHC for C-kit presentation. We used positive GIST slides as controls. Epi-info ver 6.04 (CDC, WHO) was used for analysis. Results: C-kit was negative in all breast cancer specimens. C-kit was negative in 47 (78%) of 60 non-cancerous breast tissue specimens, but was positive in 13 (22%) of them (p < 0.0001). Conclusions: There is a reduction in C-kit expression with malignant transformation of breast epithelium. C-kit is believed to play a role in breast carcinogenesis. However, we should follow patients with normal or benign breast tissue to indicate any correlation between C-kit presentation and breast cancer development.
引用
收藏
页码:306 / 309
页数:4
相关论文
共 25 条
  • [1] EXPRESSION OF STEM-CELL FACTOR AND ITS RECEPTOR BY HUMAN NEUROBLASTOMA-CELLS AND TUMORS
    BECK, D
    GROSS, N
    BROGNARA, CB
    PERRUISSEAU, G
    [J]. BLOOD, 1995, 86 (08) : 3132 - 3138
  • [2] Bellone G, 1997, J CELL PHYSIOL, V172, P1, DOI 10.1002/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO
  • [3] 2-S
  • [4] CANTLEY L, 2008, DEVITA HELLMAN ROSEN, P67
  • [5] Diallo R, 2006, Verh Dtsch Ges Pathol, V90, P177
  • [6] DiPaola RS, 1997, CANCER GENE THER, V4, P176
  • [7] The stem cell factor-c-kit system and mast cells in human pancreatic cancer
    Esposito, I
    Kleeff, J
    Bischoff, SC
    Fischer, L
    Collecchi, P
    Iorio, M
    Bevilacqua, G
    Büchler, MW
    Friess, H
    [J]. LABORATORY INVESTIGATION, 2002, 82 (11) : 1481 - 1492
  • [8] Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Fletcher, CDM
    Berman, JJ
    Corless, C
    Gorstein, F
    Lasota, J
    Longley, BJ
    Miettinen, M
    O'Leary, TJ
    Remotti, H
    Rubin, BP
    Shmookler, B
    Sobin, LH
    Weiss, SW
    [J]. HUMAN PATHOLOGY, 2002, 33 (05) : 459 - 465
  • [9] HIBI K, 1991, ONCOGENE, V6, P2291
  • [10] Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    Hirota, S
    Isozaki, K
    Moriyama, Y
    Hashimoto, K
    Nishida, T
    Ishiguro, S
    Kawano, K
    Hanada, M
    Kurata, A
    Takeda, M
    Tunio, GM
    Matsuzawa, Y
    Kanakura, Y
    Shinomura, Y
    Kitamura, Y
    [J]. SCIENCE, 1998, 279 (5350) : 577 - 580